All In Biotech

Free tool

FAERS Monitor: Pyzchiva

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761425 or its brand name (Pyzchiva, Ustekinumab-Ttwe). Reports on generic versions are filed under their own applications.

Reports

191

Serious

189

99% of reports

Hospitalization

59

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • crohn^s disease27
  • drug ineffective20
  • product substitution issue18
  • dizziness15
  • abdominal pain14
  • infection14
  • condition aggravated13
  • diarrhoea12
  • off label use11
  • syncope11
  • arthralgia9
  • device difficult to use9
  • fatigue9
  • gastritis9
  • headache8

Reports by year received

View as table
YearReports
20246
2025112
202673

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,968 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
gastritisSignal937.719.9286
product substitution issueSignal1834.422.2553
device difficult to useSignal915.07.9104
syncopeSignal1112.16.8102
infectionSignal1410.76.4114
abdominal painSignal146.64.062
condition aggravatedSignal134.72.835
dizzinessSignal153.32.022
arthralgiaSignal92.41.36
diarrhoeaSignal122.01.26
drug ineffective201.71.15
headache81.40.71
off label use111.40.81
fatigue91.30.70
crohn^s disease270.00.02,867,009

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.